IPSEY - Ipsen nominates Pascal Touchon to its Board of Directors as new independent director | Benzinga
PARIS, FRANCE, 4 September 2023 – Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the co-optation of Pascal Touchon to its Board as an independent director, effective 4 October 2023, following the decision of Paul Sekhri to step down from his director role on this date due to other professional commitments.
Pascal Touchon is an experienced biotech CEO and pharma leader and is the CEO of ATARA Biotherapeutics. He has previously held leadership positions at Novartis and Servier and has served on the Board of Directors of several biotechs. He brings with him a successful track record in US biotech and global pharma, with 30-plus years of experience. He is a graduate of INSEAD, where he received his MBA.
Following this co-optation, the Board of Directors will remain composed of fourteen directors: seven women1 and seven men, including four independent directors and two directors representing the employees.
Pascal Touchon will be a member of the Nomination Committee, the Innovation and Development Committee and the Audit Committee.
At the next Shareholder's meeting there will be a request for ratification of this decision, which would remain in effect for the remainder of Paul Sekhri's term of office, until the 2026 Shareholder's meeting.
On behalf of the Board of Directors, Chairman of the Board Marc de Garidel thanks Paul Sekhri for his strong contribution and involvement to Ipsen's Board and Committees over the last five years.
ENDS
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (OTC:IPSEY). For more information, visit ipsen.com
For further information: